[Trastuzumab's association with cerebral metastases and meningeal carcinomatosis in a patient with HER2-positive breast cancer].
Ayuga Loro
Fernando
F
Jiménez Caballero
Pedro Enrique
PE
Martínez Barbeito
Maria Blanca
MB
Cruz Mora
Miguel Angel
MA
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000139:chemically induced* / Q000556:secondary*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000139:chemically induced* / Q000556:secondary*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D055756:Meningeal Carcinomatosis / Q000139:chemically induced* / Q000556:secondary*; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab